The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Interpretation of somatic POLE mutations in endometrial carcinoma
Open accessAbstract
Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) exonuclease domain define the important subtype of ultramutated tumours (‘POLE‐ultramutated’) within the novel molecular classification of endometrial carcinoma (EC). However, clinical implementation of this classifier requires systematic evaluation of the pathogenicity of POLE mutations. To address this, we examined base changes, tumour mutational burden (TMB), DNA microsatellite instability (MSI) status, POLE variant frequency, and the results from six in silico tools on 82 ECs with whole‐exome sequencing from The Cancer Genome Atlas (TCGA). Of these, 41 had one of five known pathogenic POLE exonuclease domain mutations (EDM) and showed characteristic genomic alterations: C>A substitution > 20%, T>G substitutions > 4%, C>G substitutions < 0.6%, indels < 5%, TMB > 100 mut/Mb. A scoring system to assess these alterations (POLE‐score) was developed; based on their scores, 7/18 (39%) additional tumours with EDM were classified as POLE‐ultramutated ECs, and the six POLE mutations present in these tumours were considered pathogenic. Only 1/23 (4%) tumours with non‐EDM showed these genomic alterations, indicating that a large majority of mutations outside the exonuclease domain are not pathogenic. The infrequent combination of MSI‐H with POLE EDM led us to investigate the clinical significance of this association. Tumours with pathogenic POLE EDM co‐existent with MSI‐H showed genomic alterations characteristic of POLE‐ultramutated ECs. In a pooled analysis of 3361 ECs, 13 ECs with DNA mismatch repair deficiency (MMRd)/MSI‐H and a pathogenic POLE EDM had a 5‐year recurrence‐free survival (RFS) of 92.3%, comparable to previously reported POLE‐ultramutated ECs. Additionally, 14 cases with non‐pathogenic POLE EDM and MMRd/MSI‐H had a 5‐year RFS of 76.2%, similar to MMRd/MSI‐H, POLE wild‐type ECs, suggesting that these should be categorised as MMRd, rather than POLE‐ultramutated ECs for prognostication. This work provides guidance on classification of ECs with POLE mutations, facilitating implementation of POLE testing in routine clinical care. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., Chapelle, A. D. L., Ruschoff, J., Fishel, R., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,183
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants
Ioannidis, N. M., Rothstein, J. H., Pejaver, V., Middha, S., McDonnell, S. K., Baheti, S., Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.08.016 · Cited by 2,908
Predicting the Functional Effect of Amino Acid Substitutions and Indels
Choi, Y., Sims, G. E., Murphy, S., Miller, J. R., & Chan, A. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046688 · Cited by 2,890
Landon, M., Saam, J., Brown, K. L., Moyes, K., Evans, B., & Wenstrup, R. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,939
Saam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
The CORGI Consortium, Palles, C., The WGS500 Consortium, Cazier, J.-B., Howarth, K. M., Domingo, E., Jones, A. M., Broderick, P., Kemp, Z., Spain, S. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2503 · Cited by 997
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S., Yang, W., Lum, A., Senz, J., Boyd, N., Pike, J., Anglesio, M., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 975
Self-citationA clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
Self-citationStelloo, E., Nout, R. A., Osse, E. M., Jürgenliemk-Schulz, I. J., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 846
Self-citationKommoss, S., McConechy, M. K., Kommoss, F., Leung, S., Bunz, A., Magrill, J., Britton, H., Kommoss, F., Grevenkamp, F., Karnezis, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy058 · Cited by 776
Self-citationPANTHER version 10: expanded protein families and functions, and analysis tools
Mi, H., Poudel, S., Muruganujan, A., Casagrande, J. T., & Thomas, P. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1194 · Cited by 770
Comprehensive Analysis of Hypermutation in Human Cancer
Campbell, B. B., Light, N., Fabrizio, D., Zatzman, M., Fuligni, F., de Borja, R., Davidson, S., Edwards, M., Elvin, J. A., Hodel, K. P., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.048 · Cited by 765
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 684
Better prediction of functional effects for sequence variants
Hecht, M., Bromberg, Y., & Rost, B. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s8-s1 · Cited by 569
Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Nijman, H. W., Leary, A., Edmondson, R. J., Powell, M. E., Crosbie, E. J., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.43 · Cited by 486
Self-citationNIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Le Gallo, M., O'Hara, A. J., Rudd, M. L., Urick, M. E., Hansen, N. F., O'Neil, N. J., Price, J. C., Zhang, S., England, B. M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2455 · Cited by 419
Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas
León‐Castillo, A., Gilvazquez, E., Nout, R., Smit, V. T., McAlpine, J. N., McConechy, M., Kommoss, S., Brucker, S. Y., Carlson, J. W., Epstein, E., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5373 · Cited by 415
Self-citationSomatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Kim, J., Mouw, K. W., Polak, P., Braunstein, L. Z., Kamburov, A., Tiao, G., Kwiatkowski, D. J., Rosenberg, J. E., Van Allen, E. M., D'Andrea, A. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3557 · Cited by 413
A panoply of errors: polymerase proofreading domain mutations in cancer
Rayner, E., van Gool, I. C., Palles, C., Kearsey, S. E., Bosse, T., Tomlinson, I., & Church, D. N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.12 · Cited by 373
Self-citationDNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer
Church, D. N., Briggs, S. E. W., Palles, C., Domingo, E., Kearsey, S. J., Grimes, J. M., Gorman, M., Martin, L., Howarth, K. M., Hodgson, S. V., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt131 · Cited by 352
Self-citationPrognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
Church, D. N., Stelloo, E., Nout, R. A., Valtcheva, N., Depreeuw, J., ter Haar, N., Noske, A., Amant, F., Tomlinson, I. P. M., Wild, P. J., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju402 · Cited by 332
Self-citationLandscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
Zhao, S., Choi, M., Overton, J. D., Bellone, S., Roque, D. M., Cocco, E., Guzzo, F., English, D. P., Varughese, J., Gasparrini, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222577110 · Cited by 320
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 320
Self-citationSingh, N., Piskorz, A. M., Bosse, T., Jimenez‐Linan, M., Rous, B., Brenton, J. D., Gilks, C. B., & Köbel, M. (2020) · The Journal of Pathology · doi:10.1002/path.5375 · Cited by 316
Self-citationShinbrot, E., Henninger, E. E., Weinhold, N., Covington, K. R., Göksenin, A. Y., Schultz, N., Chao, H., Doddapaneni, H., Muzny, D. M., Gibbs, R. A., et al. (2014) · Genome Research · doi:10.1101/gr.174789.114 · Cited by 278
Hussein, Y. R., Weigelt, B., Levine, D. A., Schoolmeester, J. K., Dao, L. N., Balzer, B. L., Liles, G., Karlan, B., Köbel, M., Lee, C.-H., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.143 · Cited by 220
Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
McConechy, M. K., Talhouk, A., Leung, S., Chiu, D., Yang, W., Senz, J., Reha-Krantz, L. J., Lee, C.-H., Huntsman, D. G., Gilks, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2233 · Cited by 190
Self-citationMeng, B., Hoang, L. N., McIntyre, J. B., Duggan, M. A., Nelson, G. S., Lee, C.-H., & Köbel, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.05.006 · Cited by 185
Haradhvala, N. J., Kim, J., Maruvka, Y. E., Polak, P., Rosebrock, D., Livitz, D., Hess, J. M., Leshchiner, I., Kamburov, A., Mouw, K. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04002-4 · Cited by 183
Billingsley, C. C., Cohn, D. E., Mutch, D. G., Stephens, J. A., Suarez, A. A., & Goodfellow, P. J. (2015) · Cancer · doi:10.1002/cncr.29046 · Cited by 176
New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis
Valle, L., Hernández-Illán, E., Bellido, F., Aiza, G., Castillejo, A., Castillejo, M.-I., Navarro, M., Seguí, N., Vargas, G., Guarinos, C., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu058 · Cited by 160
Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Talhouk, A., Derocher, H., Schmidt, P., Leung, S., Milne, K., Gilks, C. B., Anglesio, M. S., Nelson, B. H., & McAlpine, J. N. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3241 · Cited by 160
Self-citationClinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Soumerai, T. E., Donoghue, M. T. A., Bandlamudi, C., Srinivasan, P., Chang, M. T., Zamarin, D., Cadoo, K. A., Grisham, R. N., O'Cearbhaill, R. E., Tew, W. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0412 · Cited by 146
Eggink, F. A., van Gool, I. C., Leary, A. F., Pollock, P. M., Crosbie, E. J., Mileshkin, L., Jordanova, E. S., Adam, J., Freeman-Mills, L., Church, D. N., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1264565 · Cited by 132
Self-citationCombined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers
Jansen, A. M. L., van Wezel, T., van den Akker, B. E., García, M. V., Ruano, D., Tops, C. M. J., Wagner, A., Letteboer, T. G. W., Gómez-García, E. B., Devilee, P., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.252 · Cited by 128
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Bellone, S., Bignotti, E., Lonardi, S., Ferrari, F., Centritto, F., Masserdotti, A., Pettinella, F., Black, J., Menderes, G., Altwerger, G. H., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.023 · Cited by 84
Bellone, S., Centritto, F., Black, J., Schwab, C. L., English, D. P.-G., Cocco, E., Lopez, S., Bonazzoli, E., Predolini, F., Ferrari, F., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.027 · Cited by 76
Wong, A., Kuick, C. H., Wong, W. L., Tham, J. M., Mansor, S., Loh, E., Jain, S., Vikas, N. N., Tan, S. H., Chan, S. H., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.031 · Cited by 43
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Self-citationLeón-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00549 · Cited by 855
Self-citationSingh, N., Piskorz, A. M., Bosse, T., Jimenez‐Linan, M., Rous, B., Brenton, J. D., Gilks, C. B., & Köbel, M. (2020) · The Journal of Pathology · doi:10.1002/path.5375 · Cited by 316
Self-citationShah, S. M., Demidova, E. V., Ringenbach, S., Faezov, B., Andrake, M., Gandhi, A., Mur, P., Viana-Errasti, J., Xiu, J., Swensen, J., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0312 · Cited by 16
Metadata
- Authors
- León‐Castillo, A., Britton, H., McConechy, M. K., McAlpine, J. N., Nout, R., Kommoss, S., Brucker, S. Y., Carlson, J. W., Epstein, E., Rau, T. T., Bosse, T., Church, D. N., & Gilks, C. B.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2020-01-29
- Volume
- 250
- Issue
- 3
- Pages
- 323-335
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2996314623
- Cited by
- 409
- References
- 43
- FWCI
- 28.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
